No.14 1995
Contents
1. Table 2 bp 30 80 90 120 E s o amp 25 22 17 13 10 T 10 24 18 10 10 TUAM 12 11 9 B 10 x su 1 1 No l 2 1 No 5 51 Construction of Image Database for High Performance Liquid Chromatography Division of Analytical Chemistry Toyama Pharmaceutical Research association mE REZ Kazuo EN2. x RR 1 63 p 103 2 2 p 88 67
3. Cucuma zedoaria Roscoe Zingiberaceae H n e o HRS Tork 4 4
4. 4 Kid98 R G B E 4 n 53 Diet 17 MAG Magd 5 Digita1 Tools Digital Wave Inc
5. D PC IN503G RS 232C 2 F Card Z STAFF Kid98 3
6. x 73 1 Ther Res 10 977 979 1989 62 Studies on Standardization of Crude Drug Components WI Evaluation of Commercial Conjugated Bile Acids Division of Analytical Chemistry Toyama Pharmaceutical Reserch Association u Kaori HASE Kyoei Pharmaceutical Co LTD X X 56 3E S508 Akemi OTSUKA Daiichi Medicine Co LTD Takahi ISHIDA dj Mayumi YOSHIZAKI Daiichi Pharmaceutical Co LTD Om 8 5 F KARRA Hideko NAKANO Daido Pharmaceutical Co LTD Hiroko FUIITA Chuo Yakuhin Co LTD Yukiko OMACHI Matsui Pharmaceutical Co LTD ERRA Machiko AOKI Meiji Pharmaceutical Co LTD BOCK WT 1 Keiko ASAMIZU Meisei Pharmaceutical Co LTD i Youichi YOKOTA Toyama Prefectural Institute for Pharmaceutic
7. PAF 1 1 2 4 RERED PAF m m OG XZEEAGARU W dat rater 1 OYERE S STREXON na an anng oo GZm1 A 0 P 235 Vv P A F 05M Ove 10ng nn AIK G 9 0 0 TRGEREGRIAA 10 0t43 15 54139 EIE 1907 aotar 54051322 dida B ETAIRA 107 101 59 10 3 oat RD 103 73s 8 1 inizi s 1035 amp 6 assamiti EN 20 i5 Bot L3 Lira 1223 IBSA L4 20t At 148 15 mABERSIT 107 It 5 9 2x12 LI ha 103 133423 WIES gL6E ORI HARAITH to 2 8 1 4 8 6 5 74100 193 CESES 22 5 13 2 Max n3 EFRIFA 10 2245 3 LERET EXE 10 Im8 5 0SE 66 Ihat 6 Tr 20uM 45 325115 E 55M 5025148 cv a988 1054 30 2 10 0 a sean value x5D of 4 8 samples 46 O10 g m4 2
8. 3 E b RI ind 530 2 HPLC ODS 1 6 GUDC GHDO GCDC 3 9 STR ODS I L column 3 Ei Lichrospher Rp Selec NATU CAPCELL PAK C18 B MERCK Ed 1 4 6x150m Column femp 40 Flow rate 0 7mg min Xobile phase 0 02X KiBPO nH3 0
9. Rk 1 Born G V R Aggregation of blood platelets by adenosine diphosphate and its reversal Nature 194 927 929 1962 2 Karaki H Mitsui M Nagase H Ozaki H Shibata S and Uemura D Inhibitory effect of a toxin okadaic acid isolated from the black sponge on smooth muscle and platelets Brit J Pharmacol 98 590 596 1989 9 Studies on Quality Evaluation of Kanpo Medicine IX The Changes of the Cinnamic aldehyde Contents in Cinnamon Bark Os ERT H aF Miyako YOSHII Yuko ISIDA Ruriko NAKADA E BE Hatsuhiro NISHIMOTO Ichiro NARIKAWA Research institute Toa Pharmaceutical Co Ltd Tu 210 62 BEC LOOBXAZGSSZELCOA LD
10. 2 232 e 1 m x R 2 T4232 9 3 x R 1
11. F Card Magd SHIFT 54 3 2 Table 2 2 Table 2
12. 10g 60m2 50 3 3 IE 25 5m n 50m 5 n 25 CHEL n n 5me SEP PAK SILICA Waters n 20m2 n 4 1 5m2 25 34 2m6 10g amp 2 TLC
13. 1 x 100 d EERGISEEUCUCTEGAURO3REUERWGI 1 10 AM ADP 2Na 5mM CaCl o 2 SKF buffer 10zg mg 3 0 25 BSA 3 10ng m O PAF Ca PRP 1 MPGE 2 200rpm x 8 min KUBOTA 5100 1M PGE 145mM NaCl 5 mM KCl 1 mM MgSO 0 5mM NaH PO 5 mM Glucose 0 001mM EDTA 10mM HEPES NaOH pH7 4 5 me 45 1 AM Fura 2AM 37 10
14. a 60 o S 3 PI 383 HN EE S 1 A So 40 Sum ES D e 8 msgid cx S RA I ya z EE ERER e Sr y s Rg 9 mos m OD 2 Fig 3 Fig 3 90 4 soises 90 N o 2 EIBEILUABSUBUCZGSE amp OrTIVTtF OBI Table 1 Fig 3 E 50
15. 1 HPLC 2 HPLC 1 2 3 2 Tig 2 1 PC 9801RX PC 9801
16. Eik 104 640 643 1986 2 EMG Rin 106 1137 1142 1986 3 17 984 990 1986 4 XE BB 38 73 79 1987 5 BZ Gas Liquid Chromatography Mass Spectrometry Eih 106 212 216 1986 38 Studies on Pharmaceutical Preparation of Gastrointestinal Remedies Containing Oriental Drugs Effect on Acute Gastric Ulcer in Rat OP m F t mS X f T Keiko NISHIURA Fumiko ISHIGURO Yuko HIMIZU
17. Table 1 Tabe 1 EIAS aye RYATLORQUEUAH I os NEC PC 9801RX WS D05 er 3 39 PC 9801EX MS DOS Yer 5 I B os 1 MS DOS Ver 3 3C PC 8801NS A MS DOS Ver 5 0 i i EPSON PC 286NOTEf MS DOS Ver 2 1 POC 386NOTEA Fig 2 Z 92 AO01898
18. Studies on Pharmaceutical Preparation of Gastrointestinal Remedies Containing Oriental Drugs Quality Evaluation of Material Crude Durgs OH ok F Yuko HIMIZU G RX T E T Fumiko ISHIGURO Keiko NISHIURA Taikyo Pharmaceutical Co Ltd Mineo ONUKI Ene Yoshindo Co Ltd nl Toshihar MAEKAWA Tux FOIR 4oe ox Mu T Euphorbiaceae Mallotus japonicus Musu As
19. 30 15 1 10cm 365nm 2 Sigma 5mmHg 24 20mg 1 6mM 20mg 5 mg 1 6mM 50m 5m2 2m2 200mg 1 6mM 70m2 30 1 6mM 100 mg ETA TORERE H RS m 2 m2 p 1 6mM 1 50 000 10xe HPLC
20. 39 BR E D 1 AKOBIBE 24 Wistar RES y b 150 210g AK 1 150mM 60 5 mg amp kg 3 Na60 mg kg 10 6 mg RIDERE UJ VEELE mm 1 AK AJKI AL 25 100mg m 10m kg 2 AK GA AL GU 1 AK 250mg kg 1 2 Tabie 2 Table 2 AK amp GA AL GU
21. 3 85 g 5 850m2 60 40 49 60 1 2 3 E HPLC Cosmosil 5C AR 4 6mm x150mm 274nm 1 1 1 m 7 100 1 HERD ERR 1 p E J e ds J D KAERRA Demen cazes OF EuxRzadi CA AT Fig 2 bp o 60 90 120 B B mM 30 Fig 2 R oPh bMS S MM 90 p E eer
22. 5 Ri S TLC HPLC TLC HPLC 2 2 6 2 HPLC 99 N TCDC TLC HPLC 99 HPLC GC GDC
23. 63 1 1 TLC 100 O 6mg 2mg 1m 100m2 2 A EUER 00 10 1 10cm 10 gg 0 8g 4 1 10m2 105 10 2 HPLC Q 15mg 5me MEGA 1m 100m2 2 1 1ml 20m 2 210nm 4 6mrm 10 30 cm 5 10 an
24. TV WI 1 1 2 ud X furanodienone curzerenone furanogermenone 1 WV 1 0 4 TV R 3 1 EE 90 4 0 796 V VI 1 3 TV WI 1 7 1 2 I N E E d6 V VI Wit
25. F D 52 Hn Fig 1 Tii PC 98012 Z Hi NW
26. HE AB Ca 1 amp 9 3 0 4 0kg lbo dy UAOGX ON AUCHUZ 3 2 X 7946 ADP 2Na MA NYCOMED PAF
27. 7 Corsair PC 9801RX PE PR201X Logitec NEC NEC Fig 1 2 HPLC 3
28. 1 1 17 g 4 g 3g AR3 g 2 g 582g 2 g 1g 2 2 68 4 77 2 ik 1 O 20g 1 700m Fig 1 30 607 905 120 2 170g 170 g 10 1 700m2 1 2 ERB g 5 850mg rio 1 FAEERE ER 30 50
29. 3 8 1 9 1 100rpm 10 LEOZ IMMER platelet rich plasma PRP 3 000 rpm 10 platelet poor plasma PPP PRP 5 6 x10 8 4u PPP PRP Born DHE CAF 100 1 200rpm 37C PRP400zg 2 Ko 502 2 50 gg AMARRE EAEL BERAE IN PRP PPPO 0 100
30. 1 1 1 _
31. 99 1 99 2 HPLC TLC e 2 3 2 N f f 1 j TUDC IC i i TCDC TDC IH IH 1 i IH 1 i i H i 1 H H 1 li ji i j i i i i d 1 i 1 UL Ml n uUi N Eei 3 E2gS2n0vk 54 Gur O e e 5r o 9 uo e 2 e e e oS eo e 6 9 e e9 pop a 1C THBDC TCDC TDC GC ne TC TUDC iCPC TBC GC 6 s Ni o9 e suskcHesseo yt O gmigigilk oBeosASy 66 1 2 2 99
32. HPLC HPLC C18UG120 2 4 6x20mm 10mM 56 44 1 5m2 min 40 C 345 nm 20 1 VIMEGREELZI d ZAREE 10 g m 10 g m amp 2 DI STEMD P A FE EM ET rimmge me BERTIZ YR PAF 50 ADP E 25 SE ADPAE PAF 4
33. 4 Pu ER U SEE Sigma 2 g Aldrich t d2 LC 6A CTO 6A UV SPD 6A CR 5A GC 14A CR 3A X x 1 0 X R 1 EM 10mg 1 6mM 10m2 200mg 1 6mM 10m2 5 10 zg TLC E B
34. Fura 2200rpm x 2 2 200rpm x 4min 4min 2 Fura 2 AM m 5 x10 2 Fura 2 Fnura 2 400 2 RAIK 50 2 2 PAF 50 gg Ca CAF 100 340 nm S56 ES00nm 7 200mg 500mg 100m2 BEL 10 0 45
35. Table 3 Dig CAP_001 B1 32000 94 w 9 15 CAP O0 R1 32000 94 9 15 CAP O0 61 32000 94 9 15 CAP 001 E1 32000 94 9 15 CAP 002 Bi 32000 94 9 17 CAP_002 R1 32000 94 9 17 CAP_002 61 32000 94 9 17 CAP_002 E1 32000 94 w 9 17 CAP 059 81 32000 94 w 15 01 CAP 059 R1 32000 94 15 01 CAP 059 61 32000 94 15 01 CAP 059 E1 32000 94 15 01 CAP 060 81 32000 94 15 03 CAP 060 RI 32000 94 15 04 CAP 060 61 32000 94 15 04 CAP_060 E1 32000 94 15 04 240 640000 Bytes CAP_001 81 2883 94 ww ww 9 15 CAP_001 R1 2883 94 w 9 15 CAP_001 61 2883 94 9 15 CAP 002 81 3084 94 e es 9 17 CAP 002 RI 3084 94 eee 8 17 CAP 002 Gi 3084 94 9 17 CAP_059 Bl 5949 94 www 15 01 CAP_059 RI 5949 94 ww ws 15 01 CAP_059 Gi 5949 94 15 01 CAP 060 8i 3141 94 ww ww 15 08 CAP 060 RI 3141 94 xw w 15 04 CAP_060 Gl 3141 94 4 15 04 180 54297 Bytes 1 10 1 Table 3 60 240 64
36. 1 0110 gm 38 6 4 7 86 6514 7 18 5 3 0 m uAUv 1600 6ga 440412 0 78 75 B 4 3 55 25 3 8110 Sg mt 29 3 12 8 TE 22 a PAFO3Ung n ILE DREZEN SERRER 3 5BIOTSIESE 3 1 0710 liis T AE M MACHAUE E2 FualRGULoUSAREREIONEZ AIURBHAOAECIHSTS 49vv2520EN olv 5k PAF l ng e Platelet activating factor OR Emt 1r10 s ml CV3986 10M CV3986 3 Ca Ca CV3988 Ca Ca 2 A e E M CS T MP RUE Nd S E cd um 46619 EN Pa 50
37. 93 06 10 HPLC DATABASE l No 54 Ape 54 BI 1 CI 2 DI 2 U7 7 IV vhi B12 86 81 82 E 2 F 6 b shiseido cap_054 mag SHIFT Kid98 Tit R G B FE 4 TERR P 32 000 bytes 128 000bytes 1 9 CC 4 E Diet 180 5 4 F3 FE 5B
38. HPLC LS Je Application part e lt w Non application part Flux pg cm2 h Drug permeated x g cm Time h Time h Fig 2 Permeation profile of FP to subcutaneous tissue after topical application 59 1 s Application part 64 m Non application part 1 2 4 554 1 i E 5o T a 5 084 a 0 6 3 97 2 E 5 3 A Lu ua 0 4 3 E 1 0 2 El Time h Fig 3 Permeation profile of SA to subcutaneous tissue after topical application A R T 4 6 oo Time h FP SA Fig 2 3 MERE FP 2 2 SA
39. 40 E 0 02M pH3 0 33 67 TUDC 7 TC 9 GC 12 TCDC 15 TDC 18 GDC 25 10 gg 2 10 6 1 10 gg 20 3 3 HUE E 207nm HPLC 210nm 0 5 4 Wi E GC GDC 0 1g 50m2 0 02N Na L 0 01N 5 Bg
40. 60 3 0mg Table 1 AREH GEXO EUR LUA mg 1g ma sits n bp 30 80 90 120 om ut 6 8 6 0 4 6 3 6 2 6 2 8 6 5 4 8 2 1 2 8 mm COUP 3 1 3 0 2 3 3 1 2 z 6 Table 2 Fig 3 96 30 24 60 10 1
41. FP SA Fig 4 FP VOUS ODER 2 Cuax10 4 ug m2 Tad 356 SA 4 Ca 33 8ug m T 4 7h 4 Plasma concentration ug ml 9 m E n 3 4 8 8 Time h Fig 4 Plasma concentration of FP and SA after topical application 60 Table 1 Pharmacokinetic parameters of FP and SA after intravenous administration n 3 Dose A a B p Ke Vc AUC mg kg h3 h h mi ug h ml 3 560 4 034 9 808 0 2940 0 3890 75 00 105 4 FP 1 0 x 0 336 1 293 0 582 0 0040 0 0151 4 984 29 74 8 630 0 1220 0 2630 64 18 373 7 SA 1 0 e Es zb ee 1 616 3 840 0 508 0 0148 0 1077 26 19 13 2 400 JA 4 4 N 300 4 s SA 7 3 E 7 5 i 3 3 200 x x FP p 3 Time h Fig 5 Calculated skin permeation profile by deconvolution Table 2 Pharmacokinetic parameters of FP and SA after topical application n 3 FP SA Cmax ug ml 10 4 0 6 33 83 9 Tmax h 5 30 9 4 13 0 9 AUC gg h ml 105 5 5 0 373 813 2 absorption ratio 8 6 15 8 application part Fmax pg cmz h 0 40 0 08 1 062 0 39 Tmax h 6 0 1 6 4 7 0 9 non application part Fmax gg cm2 h 6 18
42. uoe 99 1 TUD adsum uz N 97 2 GC GDC Sit 99 5 TC N 97 7 su 98 4 TCDC m NE 93 7 amp 210mnm t st 98 7 o RRS TUDC TC TCDC TDC Gc GDC TDC l Ni 98 9 o a 18 13 i 14 33 15 50 14 B9 12 40 28 32 o 15 11 14 34 i 13 22 13 72 10 83 26 05 Huicr mmam neLeNg Ce c 13 15 12 33 13 00 17 00 12 04 25 28 n 600 n76 c gt r 7 Si 99 2 97 5 x d 13 10 11 93 12 19 11 98 10 67 25 09 Gc i i NK 99 2 93 3 2z 14 373 13 233 13 478 14 398 11 485 26 185 1 1 st 99 1 96 6 x i 2 8 2 8 GDC SD 1 500 1 84 1 41 107 O 64 1 483 Ni 59 2 97 1 A cy 1043 971 10 939 14 Bh 7 52 5 566 O A Ux bESRIDDOS01 28 Na x di zdoETIBMXORCbtO3SEALE 1 E 2 65 105 od fb
43. 48x t Wo RE x Elm neant S E K 5 19 5 6 5 iE 250 5 13 0 1 A 25000 78 0 5 4 1t 1 1 AH 25060 39 1 b 6 11 3 1 GA AL GU GA234mg kg AL117mg kg GU120mg kg GA AL 5 GU Table 8 Table 8 GA AL GU 853 g kg 8 x 8 8 5 Elm neant T X 6 11 4t 8 1 234 5 418 12 11 8 M tu 5 52 980 GU 120 5 5 1 8 t 0 05 wi 2 AK 250mg kg 750mg kg 6 500mg kg Table 9 Table 9 AK ABZ agt HO A amp a Eim neant S E K 5 4 11 2 1 AK 250 4 4 4 9 8 AE 500
44. Taikyo Pharmaceufica Co Ltd Bou S ox Mineo ONUKI Toshiharu MAEKAWA Yoshindo Co Ltd nl AK AL Y GA GU Euphorbiaceae Mallotus japonicus Mues Ar E 1 3 Table 1 Tabl E 3 4 lHEng Lot 7 3 2 0 7 73XRIZU 4 D 1 9 Rt E rt2 8 1 Sak 300 ESEESE FH3107 7 pr 150 Ty aERRIZN 4G 62K t j 100 8Bkkix t 083689 TAhiZ LUBA RuEE ZTGcyHUED SUUS y
45. Diet F Card i i i F Card i i Magd F Card F Card Digital Tools Fig 5 100 PART3 1992 100 PART2 1993 F Card V5 1993 Z STAFF Kid98 1993 MS DOS Diet Teddy Matsumoto 5 57 Magd TAK ARAKAWA Laboratory AAR id EJHCISIFH TH AE SEU C 55 7 JVJLC 70 7 x
46. E Diet Kid98 200 300 1 MAG MAG 1 3 55 1 Tabl 3 able 4 MAG CAP_001 81 2883 94 e 9 15 CAP_001 MAG 320194 we ww 8 56 CAP_001 Ri 2883 94 e 8 15 CAP_001 G1 2883 94 ee e 9 15 amp Fat dv sd 4 1 lt CAP_002 BI 3084 94 xw s 9 17 CAP 002 MAG 349694 w ww 8 57
47. 5 Fig 4 Fig 5 e E HPLC GC 56 D 2 3 4 5 ABCD Digital Tools J Fig 4 RYT rof R PC INS03G 1988 Em R m su x T gd TOES Kid88 Magd MAG
48. 0 05 1 110 40 Tmax h 5 3 0 9 4 7 0 9 61 3 Table 1 RRERAKO MERRER HE Fig 5 FP 45 2 8 SA 2 6 FP 8 6 SA 15 8 Table 2 E3 REUECEOHE CIEODxEUUBE ORO SFPIESAIIEACB EWB IE RRA
49. Table 4 AK i z ng g 9p 8g X k 0 0 250 53 4 375 80 01 500 9j 2H 150 87 0 1000 90 2 lt 0 05 e 2 AK GA AL GU AK GA AK GA117 2mg kg 5 Table 5 Table 5 AK GA 853 tn RR R E 8 Elm L seant S E k 5 3 7 1 A 250 6 3 2 1 1 AE 250GA 234 4 5 12 31 4 0 M 25004 117 2 5 13 0x 3 11 lt 0 05 41 La AK AL AK ALI17 0mg kg 0 1 Table 6 Table 6 AK AL ARZ rte NE R E a Kin neant S F K 5 19 11 11 5 A 280 6 10 95 2 1 AE 250HL 117 0 5 38 11 2 108 AE 250541 58 5 5 10 91 1 7 81 0 001 AK GU AK GU78mg kg 39mg kg Table 7 Table 7 AK GU
50. MM 3 BEL 2 f AE LX FP SA 3 R BRZA FP SA w w Drug Menthol EtOH PVA HO 1 2 30 5 82 58 Fig 1 In situ system e 2 EN ik D insit K B 1 3 2cm 2 Fig 1 pH7 4 3 mg h 10mg kg L HPLC 2 350g 1 3 1 mg kg
51. 50m2 EUER 200mg 100mg 70m2 15 100mx2 10m2 PERAR 5 m2 50mg BRETA 4 Hydroxy 3 methoxy benzoic acid 15000 BURHEEUSOERSEIBIRI0uEILOE HPLC Pr 272nm YMC ODS AM 6 0mm x150mm 40 0 8mZ min 3 D 3 1 1000 9 1 1 1 gg TLC BERRE H E ESESUATEOS BE SOQT UCIT E E 9 1 15cm p 100 2 1 ERG 105 5
52. BSA GIXER CV3988 A23187 PGE 72 EDTA 2Na HEPES Fura 2AM 3 ERRED 3 500m OKEEZKCE DUAL 50 3 1 3g 2g 2g 2g 10 300m 400m 2 6 7g 22 3 4 42g 22 196 7 4g 37 5 38g 26 9 4
53. D g d 100mg n 50m6 20m6 5 m 50 g 700mg 1 m2 n 15 me 2 3 nm 50m2 20m2 5m2 nn n 1 125 1 gg GC 3 J amp W DB WAX 30mx0 53mm ID 60 10 5 min 110 110 20 3 n 22 HE
54. ARIZ E VRS NARRO 3 PAF U46619 3 emJsmmcioovsqmimickisoedovreazons Solv P amp S2k OR Ext 1x10 g nl Ara 200uH Na U46619 4uM A23IBT 10u H gt PEHEZ Z k BEBE Dioma i a E Ca T a o AAAA tA ABTA n EIU TOITEAN d ARRORA R isna tnb t ab HBUCSXn SAIR DOBGEG BG WRES nO IGAO
55. VI WI 2 1 IV 38 Table 3 I I n N V M A d B D C a A A hb e 5 5 Va JI 28 BAE Tid 0 12 m 0 28 ml 0 20 me 0 32 nt 0 32 m 0 35m 0 48 mf Wt SR t NESO ui 2 n AX X E 3 X744 0242 X 0 78 y 70 53 1 72 1 33 3 1 28 Y 1 71 1r G t T J4 0 067 X 0 096 0 059 0 033 3 0 032 0 031 0 101 y CERB 7 377 32 372 88 0 61 53 6 9 4 19 3 S552 514g 3 Photo 3 3 n Ri AR up avo wh t Y E E gt gt x T Photo 3 ix GNE E m Rf BO 45 0 53124 54312 3480 ZU y bit EM T z 4 d2 1
56. A detailed study of Oren gedoku to Division of Pharmacology Toyama Pharmaceutical Research Association R HEX BE Satomi SAWADA Kokando Co Ltd E A Mitsugu SASAKURA Lead Chemical Co Ltd Kimi NAGAI Enjudo Co Ltd d Masayuki TERASAKI Chushin Yakugyo Co Ltd BOOK OU T Keiko ASAMIZU Meisei Pharmaceutical Co Ltd PP ON Masaru AOKI Nihon Iyakuhin Kogyou Co Ltd WE Tatsuo SHINOHARA Daito Co Ltd te Ryoichi IKEGAMI Toshiyuki MATSUBARA Toyama Prefectural Institute for Pharmaceutical Research Dil 1
57. Ro AKXGA AKXAL AKXGU mg ng kg ng kg ng kg AK Mt 180 250 250 250 250 250 G 3 14 4 101 1 AL 15 n 58 5 QU 100 18 39 2 TUASCKEAMVAIBEBIIT ANAS 24 Wistar 140 180g 1 2 30 21C 6 ETARE RRL 1 Table 3 Table 3 HEKRA b LABES MICI SRBE B AK AKXGU ng ng kg rg kg AK iW 150 0 150 250 250 GU 100 1 38 3 m Student t test 40 1 D AK AK Lichfield Wilcoxon ED AK ED 95 275 0mg kg 166 7 435 8 Table 4
58. mp EHE Photo lo dB 8k EROR a Nes D 8E REKO 3 4 TLC Photo 1 2 3 Table 1 4loeferox Muu Table 1 A B tt Co 4E D 1 6 14 6 14 X 4 20 X 4 53 X 2 7 25 5 34 3 6 43 3 98 5 5 50 t 1 18 35 Table 2 X A B Mt 5 8 1 10 1 1 2 95 E 14 66 14 87 13 00 X 2 2 84 14 69 14 22 12 82 3 2 47 12 13 13 13 2 75 0 25 13 83 1 47 14 360 443 12 98 0 15 1 41 3 ng 86 4 mg 89 8 mg 64 9 mg MIU A t B amp D amp CLOG 4 1 10313 E i1 11 75 4 34 X 8 58 6 74 amp 1 Hi X 57 25 ng 54 25 ng 4
59. 2 9 ng 67 4 mg HODA MI IY a 5o o Photo 2 1 RERI 4 Jm Photo 2 2 Table 2 1 1500mg 5000mg E Photo 2 3 H Loa 54v Table 3 D AREE TV
60. 354nm YMC ODS A 6 0mm x150mm Sp 1 1 000 17 5 40 xk l 0m min 2 D d 10mg 10me6 BEWEIS 500mg 500mg 10m2 5 33 2 10 M TLC a E mu Bi RB L4 A7 VERE 10cm 6 4 1 254nm UE VRERESMADO mg 50m 5m6 5m amp
61. 4 1 511 5 AE 150 4 p 110 a 60 05 0 01 AK GU AK Hh AK GU78mg kg AK GU39mg kg N b control Table 10 Table 10 AK GU ES lirke Wx ER 5 a Ein neant S E X 4 17 21 2 8 M 25 j 5 4t 2 1 AE 250400 18 0 4 1 81 1 M SEY 39 0 j 7 2 3 lt p 05 1 2 3 E s 43 Effects of Traditional Chinese Medicines on Rabbit Platelet Aggregation
62. A CAP_002 RI 3084 94 ww ws 9 17 Table 4 CAP 002 Gi 3084 94 w w 9 17 CAP_003 B1 3042 94 9 21 CAP_003 MAG 3640 94 ee e 8 57 B 3 CAP 003 Ri 3042 34 e 9 21 CAP_003 G1 3042 94 9 9 21 60 CAP_059 Bi 5949 94 ww 15 01 CAP 059 MAG 6613 94 4 9 05 180 CAP 059 RI 5949 94 e 15 01 CAP 059 GI 49 94 e e 15 01 SHAFA hTot 3 pb CAP_060 Bi 3141 94 ww es 15 03 CAP_060 MAG 3599 94 e 9 04 CAP_060 RI 3141 94 w we 15 04 k CAP_060 61 3141 94 wwee 15 04 9 60 2 E 180 54297 Bytes 60 20549 Bytes e 4 Fig 3 eu Sive WKYTLiciduchai rorem Digital Tools Fig 3
63. CH OH 33 67 Detection UY 210nn 2 m f 1 S N 1 HPLC condition Colvan STR ODSI D TLC 1 TUDC 6 TCDC 2 TC T TDC 3 GUDC 8 GCDC 4 GHDC 9 GDC Wakosil 5C18 200 Wakosil I 5 GC 5C18 HG 30 207nm 210nm 1 4 ur HP TLCfE ac6 Ce d
64. OMOTO Kokando Co Ltd Hn amp Tsuyoshi KAWASHIMA Fuji Chemical Industries Ltd OP R HB Yasuaki KAWAHARA Taikyo Pharmaceutical Co Ltd amp Takao SHIMATANI Teika Pharmaceutical Co Ltd m X Hiromi TAKAHASHI Naigai Medicine Co Ltd 8 t m Tomoe TACHI Naigai Medicine Co Ltd 88 BB Toshiaki TACHI Meiji Yakuhin Co Ltd Isao HANAZOME Toa Medicene Co Ltd H Youichi YOKOTA Toyama Prefectual Institute for Pharmaceutical Research m DR
65. al Research LT TUDC TC TCDC TDC GC GDC RT 6
66. ta PAF 24a sag usos oo d E AAT a Wr 10 u g ml 10 ng o1 GE AAK NR 0 o SDRE 3 6 XGEBGSEIGRA 1 0x10 em 50 5 18 0 82 3525 5 1 3 t0 28 8 4 3 51 3t13 8 1 Xx10 g mg 3 6x10 g DETTA 3 05 amp 1 18 051258 Ue Pe Ae ELS EN LEO wa 15x 31 3 5 33 MENIA Y zOR RSIStER PAF 0 i800 5 3 1 15 55 3 4 80x58 SD 3 AEE PDRGERGEGI ADI 010 gmi RI 5 Irun EaR umm oo PAFOKXE z 3 ng m 6 ng ml 10 ng ni HTD eet 53 5 5 4 94 3 5 7 94 8 3 1 1
67. v 2 y b insitu Study of Distribution into Subcutaneous Tisse of Flurbiprofen after Topical Application 3 Rat in situ test O Hin E Tetsukazu HAMAMOTO Mitsugu SASAKURA todo X Takayasu MATSUZAWA Harumi SUMIYOSHI X GB Hidetsune TAMAOKI Pharmaceutical Research Department Lead Chemical Co Ltd jmsipg X 1 D 9 10 ST E 22 1 50 60
Download Pdf Manuals
Related Search